NO20064238L - Imidazolinderivater med CB1 agonistlsk aktivitet - Google Patents

Imidazolinderivater med CB1 agonistlsk aktivitet

Info

Publication number: NO20064238L
Authority: NO; Norway
Prior art keywords: imidazoline derivatives; agonist activity; compounds; preparation; methods
Prior art date: 2004-02-19

Application number

NO20064238A

Other languages

English (en)

Norwegian (no)

Inventor

Herman H Van Stuivenberg

Cornelis Gerrit Kruse

Josephus H M Lange

Original Assignee

Solvay Pharm Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-02-19

Filing date

2006-09-19

Publication date

2006-11-20

2006-09-19 Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv

2006-11-20 Publication of NO20064238L publication Critical patent/NO20064238L/no

Links

229940083254 peripheral vasodilators imidazoline derivative Drugs 0.000 title abstract 4
150000002462 imidazolines Chemical class 0.000 title abstract 3
239000003554 cannabinoid 1 receptor agonist Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 2
239000000543 intermediate Substances 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
238000002360 preparation method Methods 0.000 abstract 2
-1 1,2,4-tri-substituted imidazoline Chemical class 0.000 abstract 1
208000012902 Nervous system disease Diseases 0.000 abstract 1
208000025966 Neurological disease Diseases 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
208000020016 psychiatric disease Diseases 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
- C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
- C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D233/16—Radicals substituted by nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/52—Nitrogen atoms not forming part of a nitro radical with hetero atoms directly attached to said nitrogen atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Ophthalmology & Optometry (AREA)
Pulmonology (AREA)
Addiction (AREA)
Obesity (AREA)
Psychology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Gastroenterology & Hepatology (AREA)
Reproductive Health (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

NO20064238A 2004-02-19 2006-09-19 Imidazolinderivater med CB1 agonistlsk aktivitet NO20064238L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US54548404P	2004-02-19	2004-02-19
EP04100656		2004-02-19
PCT/EP2005/050680 WO2005080345A2 (en)	2004-02-19	2005-02-16	Imidazoline derivatives having cb1-antagonistic activity

Publications (1)

Publication Number	Publication Date
NO20064238L true NO20064238L (no)	2006-11-20

Family

ID=34889023

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20064238A NO20064238L (no)	2004-02-19	2006-09-19	Imidazolinderivater med CB1 agonistlsk aktivitet

Country Status (17)

Country	Link
EP (1)	EP1725536B8 (de)
JP (1)	JP2007523128A (de)
KR (1)	KR20060131908A (de)
AT (1)	ATE411296T1 (de)
AU (1)	AU2005214084B2 (de)
CA (1)	CA2553372A1 (de)
DE (1)	DE602005010401D1 (de)
DK (1)	DK1725536T3 (de)
ES (1)	ES2315851T3 (de)
HR (1)	HRP20080689T3 (de)
IL (1)	IL176546A (de)
NO (1)	NO20064238L (de)
PL (1)	PL1725536T3 (de)
PT (1)	PT1725536E (de)
RU (1)	RU2357958C2 (de)
SI (1)	SI1725536T1 (de)
WO (1)	WO2005080345A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0715160A2 (pt)	2006-08-08	2013-06-11	Sanofi Aventis	imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
TW200825067A (en) *	2006-10-23	2008-06-16	Lilly Co Eli	CB1 compounds
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ES2390560T3 (es) *	2008-04-22	2012-11-14	Eli Lilly And Company	Compuestos de 1,5-difenil-pirrolidin-2-ona como ligandos CB-1
AU2009238444B2 (en) *	2008-04-22	2013-08-29	Eli Lilly And Company	1,5-diphenyl-pyrrolidin-2-one compounds as CB-1 ligands
WO2010003624A2 (en)	2008-07-09	2010-01-14	Sanofi-Aventis	Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en)	2008-12-08	2010-06-17	Sanofi-Aventis	A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
DK2470552T3 (en)	2009-08-26	2014-02-17	Sanofi Sa	NOVEL, CRYSTALLINE, heteroaromatic FLUORGLYCOSIDHYDRATER, MEDICINES COVERING THESE COMPOUNDS AND THEIR USE
US8933024B2 (en)	2010-06-18	2015-01-13	Sanofi	Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8710050B2 (en)	2011-03-08	2014-04-29	Sanofi	Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683704B1 (de)	2011-03-08	2014-12-17	Sanofi	Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683703B1 (de)	2011-03-08	2015-05-27	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de)	2011-03-08	2012-09-13	Sanofi	Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120050A1 (de)	2011-03-08	2012-09-13	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2766349B1 (de)	2011-03-08	2016-06-01	Sanofi	Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120058A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809325B2 (en)	2011-03-08	2014-08-19	Sanofi	Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
WO2012120054A1 (de)	2011-03-08	2012-09-13	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5616601A (en) *	1994-07-28	1997-04-01	Gd Searle & Co	1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
TWI231757B (en) *	2001-09-21	2005-05-01	Solvay Pharm Bv	1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
ES2272809T3 (es) *	2001-09-21	2007-05-01	Solvay Pharm Bv	Nuevos derivados de 4,5-dihidro-1h-pirazol con actividad antagonista de cb1.
AR038966A1 (es) *	2002-03-18	2005-02-02	Solvay Pharm Bv	Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1
US6878735B2 (en) *	2002-05-31	2005-04-12	Board Of Trustees Of Michigan State University	Multi-substituted imidazolines and method of use thereof

2005
- 2005-02-16 DK DK05716710T patent/DK1725536T3/da active
- 2005-02-16 SI SI200530522T patent/SI1725536T1/sl unknown
- 2005-02-16 AT AT05716710T patent/ATE411296T1/de active
- 2005-02-16 PT PT05716710T patent/PT1725536E/pt unknown
- 2005-02-16 RU RU2006133373/04A patent/RU2357958C2/ru not_active IP Right Cessation
- 2005-02-16 EP EP05716710A patent/EP1725536B8/de not_active Expired - Lifetime
- 2005-02-16 ES ES05716710T patent/ES2315851T3/es not_active Expired - Lifetime
- 2005-02-16 WO PCT/EP2005/050680 patent/WO2005080345A2/en not_active Ceased
- 2005-02-16 HR HR20080689T patent/HRP20080689T3/xx unknown
- 2005-02-16 KR KR1020067019318A patent/KR20060131908A/ko not_active Ceased
- 2005-02-16 JP JP2006553588A patent/JP2007523128A/ja not_active Ceased
- 2005-02-16 CA CA002553372A patent/CA2553372A1/en not_active Abandoned
- 2005-02-16 DE DE602005010401T patent/DE602005010401D1/de not_active Expired - Lifetime
- 2005-02-16 PL PL05716710T patent/PL1725536T3/pl unknown
- 2005-02-16 AU AU2005214084A patent/AU2005214084B2/en not_active Ceased
2006
- 2006-06-26 IL IL176546A patent/IL176546A/en not_active IP Right Cessation
- 2006-09-19 NO NO20064238A patent/NO20064238L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
AU2005214084A1 (en)	2005-09-01
RU2357958C2 (ru)	2009-06-10
SI1725536T1 (sl)	2009-04-30
WO2005080345A2 (en)	2005-09-01
PT1725536E (pt)	2009-01-22
ES2315851T3 (es)	2009-04-01
ATE411296T1 (de)	2008-10-15
EP1725536A2 (de)	2006-11-29
EP1725536B8 (de)	2009-04-22
IL176546A0 (en)	2006-10-31
EP1725536B1 (de)	2008-10-15
IL176546A (en)	2010-06-30
AU2005214084B2 (en)	2010-06-03
DK1725536T3 (da)	2009-02-16
JP2007523128A (ja)	2007-08-16
WO2005080345A3 (en)	2006-12-21
HRP20080689T3 (hr)	2009-05-31
DE602005010401D1 (de)	2008-11-27
CA2553372A1 (en)	2005-09-01
KR20060131908A (ko)	2006-12-20
RU2006133373A (ru)	2008-03-27
PL1725536T3 (pl)	2009-04-30

Legal Events

Date	Code	Title	Description
2012-10-01	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
TW200517388A (en)	2005-06-01	Thiazole derivatives as cannabinoid receptor modulators
DK1725536T3 (da)	2009-02-16	Imidazolin-derivater med CB1-antagonistisk aktivitet
MXPA05012840A (es)	2006-02-13	Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades.
MY140693A (en)	2010-01-15	[1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
IL187438A0 (en)	2008-02-09	Pyrrolopyridine derivatives and pharmaceutical compositions containing the same
MXPA06014721A (es)	2007-06-22	Derivados de alquinilo como moduladores de los receptores de glutamato metabotropico.
MXPA05013059A (es)	2006-03-02	Derivados de 2-amino-piridina como agonistas del adrenoceptor beta-2.
TW200503710A (en)	2005-02-01	Novel compounds
MY143581A (en)	2011-05-31	Carboxamide derivatives as muscarinic receptor antagonists
NO20080563L (no)	2008-02-01	Pyrazol[3,4-d]azepinderivater som histamin H3 antagonister
UA84896C2 (ru)	2008-12-10	Производные гидронопола как агонисты человеческих рецепторов orl1
TW200611695A (en)	2006-04-16	Pyrrolopyridine derivatives
TW200505865A (en)	2005-02-16	Compounds useful for the treatment of diseases
WO2005060959A8 (en)	2006-01-12	Pyrazole derivatives and use thereof as orexin receptor antagonists
DE602004011204D1 (de)	2008-02-21	Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
TW200519101A (en)	2005-06-16	Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
EP1736470A3 (de)	2007-04-04	Pyrimidin-Derivate als cb2 Cannabinoid-Rezeptor Modulatoren
TW200519102A (en)	2005-06-16	Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
ATE496896T1 (de)	2011-02-15	1h-imidazolderivate als modulatoren des cannabinoidrezeptors
DK1373218T3 (da)	2008-05-19	Imidazolylderivater til anvendelse som histamin H3-receptorligander
EA201071227A1 (ru)	2011-04-29	(5r)-1,5-диарил-4,5-дигидро-1h-пиразол-3-карбоксамидиновые производные, обладающие св1-антагонистической активностью
UA84737C2 (ru)	2008-11-25	Производные имидазолина с антагонистической активностью относительно cb1
TW200504075A (en)	2005-02-01	Imidazopyridine intermediates
UA89846C2 (ru)	2010-03-10	Производные карбоксамида как антагонисты мускариновых рецепторов